Year: 2022

PHOENIX, Nov. 10, 2022 (GLOBE NEWSWIRE) — QuoteMedia, Inc. (OTCQB: QMCI), a leading provider of market data and financial applications, announced financial results for the quarter ended September 30, 2022. QuoteMedia provides banks, brokerage firms, private equity firms, financial planners and sophisticated investors with a more economical, higher quality alternative source of stock market data and related research information. We compete with several larger legacy organizations and a modest community of other smaller companies. QuoteMedia provides comprehensive market data services, including streaming data feeds, on-demand request-based data (XML/JSON), web content solutions (financial content for website integration) and applications such as Quotestream Professional and Quotestream Web Trader. Highlights for Q3 2022 include...

-Gross Margin Increases 33% to $2.0 Million; Net Income Increases to $0.3 Million or $0.05 per share- -PBRT Revenue and Volume Increases 82% and 40% Respectively- -Conference Call Thursday November 10th at 3:00pm ET / 12:00pm PT- SAN FRANCISCO, CA, Nov. 10, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — American Shared Hospital Services (NYSE American: AMS) (the “Company”), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced financial results for the third quarter and nine months of fiscal 2022, ended September 30, 2022. Third Quarter 2022 Financial HighlightsTotal revenue in the third quarter was $4,828,000, an increase of 17.8% from the comparable period in 2021. Total proton therapy revenue and fractions increased...

BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) — PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the third quarter ended September 30, 2022 and highlighted recent corporate developments. “During the third quarter we reported results from our Phase 1 Healthy Normal Volunteer (HNV) clinical trial of PGN-EDO51, our lead program for the treatment of Duchenne muscular dystrophy (DMD) patients who are amenable to an exon 51 skipping approach. These results exceeded our expectations, with PGN-EDO51 exhibiting the highest levels of oligonucleotide delivery and exon skipping in a clinical trial following a single dose when compared to publicly-available...

illumin Revenue Up 78.4% YOY and 29.4% sequentiallyGenerated $29.0 million in Total Revenue(All monetary figures are expressed in Canadian dollars unless otherwise stated) TORONTO and NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) — AcuityAds Holdings Inc. (TSX:AT) (NASDAQ:ATY) (“AcuityAds” or “Company”), a Journey Advertising technology company that empowers marketers to make smarter decisions about communicating with online consumers, today announced its financial results for the three and nine months ended September 30, 2022. Third Quarter 2022 HighlightsTotal revenue for the three months ended September 30, 2022, was $29.0 million, up 2.5% sequentially and 5.5% on a year over year basis as we began to realize the benefits of our recent investments in sales, marketing, and product development. Despite significant macro-economic...

— Updated Positive Topline Data from the Phase 1/2 Trial of Botaretigene Sparoparvovec (AAV-RPGR) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) — Now Dosing Patients in Phase 1 Trial Evaluating AAV-GAD Gene Therapy for Parkinson’s Disease — Received $25.0 Million Investment from Johnson & Johnson Innovation – JJDC, Inc. (“JJDC”), the Investment Arm of Johnson and Johnson — Company to Provide Clinical Program Update for the Phase 1 AQUAx Trial of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia in December 2022 LONDON and NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) — MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage gene therapy company, today announced financial results for the third quarter ended September 30, 2022, and provided an update on...

AUSTIN, Texas, Nov. 10, 2022 (GLOBE NEWSWIRE) — Astrotech Corporation (Nasdaq: ASTC) (the “Company” or “Astrotech”) reported its financial results for the first quarter of fiscal year 2023, which ended September 30, 2022. Financial Highlights & Recent Developments Astrotech’s consolidated balance sheet remains strong with $48.9 million in cash and liquid investments, which are anticipated to support our research and development, organic growth, and potential synergistic acquisition targets. Field trials continue with our AgLAB subsidiary with promising results for the AgLAB-1000-D2™. We believe hemp and cannabis distillers can gain significant improvement on their processing yields by utilizing the AgLAB-1000-D2 system with their existing short path-molecular distillation systems. We began our first production run...

Record Revenues of $56.1 M, Driven by 25% Organic Growth Key financial highlights(All comparisons are relative to the three-month period ended September 30, 2021, unless otherwise stated)Revenue growth of 46.3% reaching $56.1 M from $38.3 M; Organic revenue growth of 25.0%, compared to 7.7%, with recurring revenues by nature of 89%; Adjusted EBITDA1 reached $5.0 M, compared to $4.0 M; Breakeven net earnings, compared to net earnings of $0.6 M; and adjusted net earnings1 of $2.6 M or $0.029 per share, compared to $2.1 M or $0.025 per share; and Consolidated backlog of $182.0 M as at the end of the first quarter of fiscal year 2023, up to 48.2%.All amounts in Canadian dollars unless otherwise stated. QUEBEC CITY, Nov. 10, 2022 (GLOBE NEWSWIRE) — (TSX: HEO) – H2O Innovation Inc. (“H2O Innovation” or the “Corporation”) announces...

Validive® Phase 2b/3 Interim Analysis on Track for Q1 2023Camsirubicin Clinical Data at CTOS 2022 Next WeekMNPR-202 Preclinical Data at ASH 2022 in December WILMETTE, Ill., Nov. 10, 2022 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced third quarter 2022 financial results and summarized recent program developments. Recent Program Developments Validive – International Phase 2b/3 Trial, Interim Go/No-go Analysis on Track for Q1 2023The VOICE trial continues to enroll patients and add additional clinical sites (now at 73 active sites and over 130 patients dosed across the U.S. and Europe). Enrollment for the Phase...

– Extended and broadened its ongoing research collaboration with Regeneron, a leading U.S. biotechnology company – – Announces CLS-001 as subcutaneous formulation of vedolizumab, a currently marketed monoclonal antibody for the treatment of inflammatory bowel disease (IBD) – WOBURN, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) — Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today reported financial results for the quarter ended September 30, 2022 and provided a business update. “We are extremely pleased with our progress this quarter. We have made significant advancements in strengthening our internal pipeline, team and capabilities, highlighted by a recent extension and expansion of one of...